» Articles » PMID: 20220781

An Ex Vivo Loop System Models the Toxicity and Efficacy of PEGylated and Unmodified Adenovirus Serotype 5 in Whole Human Blood

Overview
Journal Gene Ther
Date 2010 Mar 12
PMID 20220781
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Polyethylene glycol coating (PEGylation) of adenovirus serotype 5 (Ad5) has been shown to effectively reduce immunogenicity and increase circulation time of intravenously administered virus in mouse models. Herein, we monitored clot formation, complement activation, cytokine release and blood cell association upon addition of uncoated or PEGylated Ad5 to human whole blood. We used a novel blood loop model where human blood from healthy donors was mixed with virus and incubated in heparin-coated PVC tubing while rotating at 37 degrees C for up to 8 h. Production of the complement components C3a and C5a and the cytokines IL-8, RANTES and MCP-1 was significantly lower with 20K-PEGylated Ad5 than with uncoated Ad5. PEGylation prevented clotting and reduced Ad5 binding to blood cells in blood with low ability to neutralize Ad5. The effect was particularly pronounced in monocytes, granulocytes, B-cells and T-cells, but could also be observed in erythrocytes and platelets. In conclusion, PEGylation of Ad5 can reduce the immune response mounted in human blood, although the protective effects are rather modest in contrast to published mouse data. Our findings underline the importance of developing reliable models and we propose the use of human whole blood models in pre-clinical screening of gene therapy vectors.

Citing Articles

Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular application of the vaccine?.

Gurtler L, Seitz R, Schramm W Infection. 2021; 49(5):1071-1074.

PMID: 34286453 PMC: 8294245. DOI: 10.1007/s15010-021-01658-x.


Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy.

Wenthe J, Naseri S, Labani-Motlagh A, Enblad G, Wikstrom K, Eriksson E Cancer Immunol Immunother. 2021; 70(10):2851-2865.

PMID: 33666760 PMC: 8423656. DOI: 10.1007/s00262-021-02895-7.


Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40.

Wenthe J, Naseri S, Hellstrom A, Wiklund H, Eriksson E, Loskog A Cancer Gene Ther. 2020; 27(12):948-959.

PMID: 32355275 PMC: 7725669. DOI: 10.1038/s41417-020-0176-9.


Retargeting adenoviruses for therapeutic applications and vaccines.

Barry M, Rubin J, Lu S FEBS Lett. 2020; 594(12):1918-1946.

PMID: 31944286 PMC: 7311308. DOI: 10.1002/1873-3468.13731.


Systemic Administration and Targeted Delivery of Immunogenic Oncolytic Adenovirus Encapsulated in Extracellular Vesicles for Cancer Therapies.

Garofalo M, Villa A, Rizzi N, Kuryk L, Mazzaferro V, Ciana P Viruses. 2018; 10(10).

PMID: 30322158 PMC: 6213631. DOI: 10.3390/v10100558.